

REMARKS

Claims 22, 23, and 25-28 have been cancelled and claims 20, 24, and 32 amended herewith. Support for the amendments to claims 20, 24, and 32 lies in the original claims and specification as filed. See, for example, at page 3, lines 4-20, page 13, line 24 through page 14 line 28.

Claims 20, 21, 24-28, and 32 were rejected under 35 USC §112 for lack of sufficient written description. The rejection is traversed.

Claims 22, 23, and 25-28 have been cancelled, rendering the rejection to these claims moot. Claims 20, 24, and 32 have been amended to further clarify the GLUTX gene as nucleic acid sequences that encode SEQ ID NO:2. Applicants submit the Examiner has acknowledged that the specification discloses sequences which encodes SEQ ID NO:2. Further, Applicants submit the knowledge of skill in the art, in combination of Applicants disclosure of the specification as filed provide sufficient direction to enable those of skill in the art to ascertain Applicants were in possession of the presently claimed methods at the time of filing of the application.

Additionally, Applicants disclosure provides sufficient description of modulators of hexose uptake by modulating expression of GLUTX using antisense or ribozyme oligonucleotides capable of inhibition of expression of a GLUTX gene encoding SEQ ID NO:2. See e.g., at pages 36, line 17 through page 43, line 10.

In view of the present amendments, Applicants submit the rejections under 35 USC §112 are overcome and the claims allowable. Reconsideration and withdrawal of the rejections is requested.

This paper is being filed timely and it is believed no fees or extensions of time are required. In the event any fees or extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

29 June 2004

MILLENNIUM PHARMACEUTICALS, INC.

By


Kerri Pollard Schray
Registration No. 47066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3676
Facsimile - 617-551-8820